Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.
We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.
In November, 2014, we announced a merger with Copenhagen-based Ventac Partners. The combination of Lacerta Bio and Ventac Partners will dramatically increase the types of services we can offer our clients, as well as expand our geographic reach.
If you need assistance finding or assessing business development and/or partnership opportunities, contact us at firstname.lastname@example.org.
Lacerta Bio is seeking parenteral products for in-licensing on behalf of a US-based client. Key criteria are: Products which can be developed via the 505(b)(2) regulatory process in the US No specific therapeutic area Injectable could be infusion, prefilled syringe, or related presentation Products already approved outside the US are especially welcome Delivery / formulationRead More»
Lacerta Bio is looking to transact a business acquisition opportunity in the European injectables manufacturing sector. We are seeking manufacturing facilities which have the following criteria: Based in Western Europe EU approved manufacturing of parenteral products Could be a stand-alone company which manufactures its own products, or the divestment of a manufacturing facility owned byRead More»
Would You Like To Expand Your Business Into China? Or Perhaps You Seek An Investor or Development Partner? China is a large and growing opportunity for Western life science companies, as: Life Science in China is Booming – China’s life science industry has been growing at more than 20%+ per year, and is expect toRead More»
Our friends at PharmaCircle recently published an interesting and provocative piece entitled Injectables: The New Oral? The PDF is available here.
The article notes that, in 2014, seven of the top ten pharmaceuticals were parenteral products, with products such as Humira, Remicade, and Enbrel achieving $9-12+ billion in sales.
This is a huge change from ten years previously, where only one parenteral product (Epogen) was in the top ten.
The article discusses some of the key reasons why this change has taken place:
So where do parenterals go from here? We think there are a few areas where parenterals could indeed approach the levels of usage of oral therapies:
Lower Dosing – Highly potent peptides and proteins which can be dosed at ~2 milligrams or less are perfect for any number of self-injection devices, skin-permeating patches, and other delivery devices which can greatly expand their use.
We think low-dose, higher frequency regimens, via novel devices will become more common in the future.
Smaller Large Molecules – Scanning the list of top 10 drugs for 2014, seven are large molecules, and only two (Lantus and Enbrel) are not monoclonal antibodies. Even with Enbrel, we are looking at a molecular weight of roughly 50,000 daltons, while Lantus checks in at a svelte ~6,000 daltons.
As our collective understanding of both disease and drug-target interactions improve, might we see these molecular weights decline? Maybe. Maybe not. But if they do, then self-dosing becomes increasingly possible.
Novel Combinations – Lower doses with small molecules opens up the theoretical possibility of parenteral combination therapies via self-injection. Perhaps small molecules and large peptides/small proteins can be combined in single, self-injection systems for severe inflammation (i.e., later-stage Crohn’s Disease), for maintaining cancer remission, and other medical needs.
Stability issues aside, patients who are using both oral and parenteral therapies could benefit from combining them into a single parenteral. While increasing Rx cost, it could increase compliance and improve overall therapeutic benefit.
So will parenterals ever become as common as orals? Probably not. But the premise of the article is quite sound, in the sense that parenteral products will continue to become more routine, thanks in part to easy-to-use self injection systems and devices.
How was Bio Europe in Stockholm last week? The Conference Itself – For us, the conference was terrific. We had nearly 30 high-quality meetings over the three days of partnering, plus more informal meetings and catch-ups at the receptions and dinners. As usual, we did not attend any of the company presentations or round-table discussions,
We’re late to the this party, but HBM Partners issued their two annual reports on M&A Activity and New Drug Approvals. Both reports also have Excel files with raw data for analysis. Below are a few highlights which caught our eye: M&A Activity – By numerous measures, 2015 was a record year, especially in terms
At last month’s Biotech Showcase, a panel discussion was held discussing different models for advancing assets without resorting to a license. The link to the discussion is here. It was an interesting discussion because each speaker detailed their own experience in advancing assets without partnering. Examples include risk sharing relationships with CROs and investors. A few